ER-KANG(SZ:300267)2022-12-07 09:31Group 1: Company Position and Market Overview - The company is the world's first industrial producer of starch capsules and the only entity in China with a "National Engineering Research Center for Pharmaceutical Excipients" [2] - The company holds 39 national authorized patents and has stable partnerships with over 3,000 pharmaceutical companies across more than 30 provinces and cities in China [2][3] Group 2: Project Details - The non-public stock issuance project aims to produce 100 billion starch plant capsules and 30 billion starch plant soft capsules annually [2] - The total investment for the project is 2.5 billion RMB, with a construction period of 2 years [3] - Upon completion, the project is expected to generate an annual sales revenue of 3.84 billion RMB and a net profit of 1.3 billion RMB, indicating strong profitability and investment recovery potential [3] Group 3: Product Advantages - The starch plant capsules are made from 100% natural starch, ensuring safety and eliminating risks associated with animal-derived materials [3] - The capsules do not undergo cross-linking reactions, making them safe for use with common chemical drugs and traditional Chinese medicine [3] - The production process avoids any chemical additives, preservatives, or colorants, enhancing product safety [3] - The stability of the capsules is high due to their single-component structure, which is less prone to bacterial growth and spoilage [3] - The company has a subsidiary in Cambodia that produces 180,000 tons of cassava starch annually, ensuring a steady supply of raw materials for capsule production [3] Group 4: Marketing Strategy - The company employs a distributor-first sales model, leveraging existing sales networks of local distributors for rapid product promotion [4]